Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 11441
  • Home
  • Print this page
  • Email this page

   Table of Contents      
LETTER TO THE EDITOR
Year : 2008  |  Volume : 56  |  Issue : 3  |  Page : 259

Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy


Central Florida Retina Consultants, University of Central Florida, School of Medicine, Orlando, Florida, USA

Date of Web Publication22-Apr-2008

Correspondence Address:
Saad Shaikh
44 Lake Beauty Drive Suite 300, Orlando, Florida 32806
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0301-4738.40380

Rights and Permissions

How to cite this article:
Shaikh S. Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy. Indian J Ophthalmol 2008;56:259

How to cite this URL:
Shaikh S. Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy. Indian J Ophthalmol [serial online] 2008 [cited 2020 Feb 27];56:259. Available from: http://www.ijo.in/text.asp?2008/56/3/259/40380

Dear Editor,

A 32-year-old African-American female with type SC sickle cell disease presented with vitreous hemorrhage in her right eye of 2 weeks' duration. Her visual acuity was 20/25 in the right eye and 20/20 in the left eye. An active area of sea fan neovascularization was noted in the superotemporal periphery of the right eye. Vitreous hemorrhage emanating from the lesion precluded adequate visualization of the retinal periphery and administration of laser therapy. Over the following week, the patient's vision decreased to 20/40. She was offered a conservative course of observation until sufficient clarity could be obtained for laser therapy, but she had become severely anxious over perceived loss of vision and had required psychiatric counseling.

After a discussion of the potential risks and benefits of off-label bevacizumab (Avastin) use, the patient signed a comprehensive consent form and underwent pars plana injection of 1.25 mg of bevacizumab. Two weeks later, her visual acuity had returned to 20/25 and the vitreous hemorrhage had near-completely cleared with incipient fibrosis of the neovascular lesion. A month later, her vision was 20/20 and examination demonstrated complete resolution of vitreous hemorrhage with fibrous involution of the neovascular complex. Angiography demonstrated diffuse peripheral capillary ischemia but no areas of active neovascularization. Laser photocoagulation was not performed. She remained without recurrent hemorrhage or neovascularization at last follow-up 6 months postinjection.

The use of anti-vascular endothelial growth factor (anti-VEGF) therapy significantly altered the acute history of proliferative sickle retinopathy in our patient. We might have anticipated the progression of neovascularization or at least the persistence of vitreous hemorrhage without surgical intervention in the form of laser therapy or vitrectomy. Our experience here, and a similar case reported previously, demonstrate that intravitreal bevacizumab can induce rapid regression of neovascularization and resolution of vitreous hemorrhage secondary to proliferative sickle retinopathy. [1] Although we are unable to state whether anti-VEGF therapy changes the long-term history and prognosis of the disease and incidence of future complications, intravitreal bevacizumab injection may have a role in the primary and/or adjunct therapy of neovascular complications of sickle cell retinopathy. Further study on the role of anti-VEGF therapy in proliferative sickle retinopathy is warranted.

 
  References Top

1.
Siqueira RC, Costa RA, Scott IU, Cintra LP, Jorge R. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmol Scand 2006;84:834-5.  Back to cited text no. 1
    



This article has been cited by
1 Intravitreal Ranibizumab for Stage IV Proliferative Sickle Cell Retinopathy: A First Case Report
Panagiotis G. Mitropoulos,Irini P. Chatziralli,Efstratios A. Parikakis,Vasileios G. Peponis,Georgios A. Amariotakis,Marilita M. Moschos
Case Reports in Ophthalmological Medicine. 2014; 2014: 1
[Pubmed] | [DOI]
2 BEVACIZUMAB PRESURGICAL TREATMENT FOR PROLIFERATIVE SICKLE-CELL RETINOPATHY-RELATED RETINAL DETACHMENT
Ala Moshiri,Nguyen Khoi Ha,Fang S. Ko,Adrienne W. Scott
Retinal Cases & Brief Reports. 2013; 7(3): 204
[Pubmed] | [DOI]
3 Sickle Cell Disease and the Eye: Old and New Concepts
Mohammed Elagouz, Sreedhar Jyothi, Bhaskar Gupta, Sobha Sivaprasad
Survey of Ophthalmology. 2010; 55(4): 359
[VIEW] | [DOI]
4 Off with the label and on the Avastin bandwagon: Why now and how far
Santhan Gopal, K.S.
Indian Journal of Ophthalmology. 2009; 57(4): 253-256
[Pubmed]
5 Bevacizumab (Avastin) for the Treatment of Ocular Disease
Gunther, J.B., Altaweel, M.M.
Survey of Ophthalmology. 2009; 54(3): 372-400
[Pubmed]
6 Bevacizumab (Avastin) for the Treatment of Ocular Disease
Jonathan B. Gunther,Michael M. Altaweel
Survey of Ophthalmology. 2009; 54(3): 372
[Pubmed] | [DOI]
7 Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
MINTZ-HITTNER, H.A. and KUFFEL JR, R.R.
Retina. 2008; 28(6): 831
[Pubmed]
8 Combination of laser photocoagulation and intravitreal bevacizumab (Avastin{\textregistered}) for aggressive zone I retinopathy of prematurity
Chung, E.J. and Kim, J.H. and Ahn, H.S. and Koh, H.J.
Graefeæs Archive for Clinical and Experimental Ophthalmology. 2007; 245(11): 1727-1730
[Pubmed]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed2238    
    Printed45    
    Emailed1    
    PDF Downloaded275    
    Comments [Add]    
    Cited by others 8    

Recommend this journal